Guardant Health Set to Benefit From Genomic Profiling Growth, RBC Says

MT Newswires Live06-12 23:03

Guardant Health (GH) is positioned to benefit from growth opportunities in tumor profiling business, RBC Capital Markets said in a Thursday report.

The report said its core tumor profiling business is vastly underpenetrated, with a recent study found only about 25% of metastatic cancer patients in the US receive genomic profiling.

"Guardant, as the market leader, is best positioned to benefit as adoption expands," the report said.

The recent approval of Guardant360 Liquid CDx should unlock a meaningful volume opportunity, while growing use of Guardant Reveal for therapy response monitoring should have positive knock-on effects for G360 demand, the report said.

The note also pointed to other catalysts, including pending Medicare coverage decisions for Guardant Reveal.

RBC initiated coverage on the stock with an outperform rating and a $185 price target.

Price: 132.69, Change: +1.79, Percent Change: +1.37

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment